EUVIMEDEUVIMED entdecken
Übersichtsarbeit

VEGF, Angiopoietin-1 and -2 in Bronchial Asthma: New Molecular Targets in Airway Angiogenesis and Microvascular Remodeling

Hiroshi Kanazawa

Recent Patents on Inflammation & Allergy Drug Discovery · 2007

DOI: 10.2174/187221307779815066 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Recent Patents on Inflammation & Allergy Drug Discovery, 2007. Verfasst von Hiroshi Kanazawa. Beteiligte Einrichtung: Department of Respiratory Medicine, Graduate School of Medicine, Osaka City University, 1-4-3, Asahi-machi, Abenoku, Osaka, 545-8585, Japan. kanazawa…. Hauptthemen laut MEDLINE: Drug Delivery Systems. Die Arbeit wurde bisher 28-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Airway angiogenesis and microvascular remodeling are known features of bronchial asthma, but the mechanisms of these structural alterations are just beginning to be elucidated. Vascular endothelial growth factor (VEGF), one of the most potent angiogenic factors, stimulates endothelial cell proliferation and induces the angiogenesis. Recently, considerable attentions have been devoted to the physiological roles of angiopoietin (Ang)-1 and -2 as regulatory factors of VEGF. Ang-1 has been shown to induce the migration and sprouting of endothelial cells, and coexpression of Ang-1 and VEGF enhanced angiogenesis. In the presence of high levels of VEGF, Ang-2 also promotes rapid increase in capillary diameter, remodeling of the basal lamina, proliferation and migration of endothelial cells, and stimulates sprouting of new blood vessels. Thus, VEGF, Ang-1 and -2 may play complementary and coordinated roles in airway angiogenesis and microvascular remodeling, and these structural changes are potentially reversible by therapeutic intervention. The scope of the present review is to discuss from a clinical point of view the potential interactions between VEGF and angiopoietins in the asthmatic airways, and focus on the therapeutic implications targeting for these angiogenic factors. Recently, there is an increasing number of patents which have been focused on the inhibitors of VEGF action. These inhibitors are directed towards the receptors of VEGF or intracellular substrates for the receptors. We will also discuss several patents regarding inhibitors of VEGF action in the present review.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Delivery SystemsAngiopoietin-1Angiopoietin-2AnimalsAsthmaGene ExpressionHumansMicrocirculationNeovascularization, PathologicPatents as TopicReceptors, Vascular Endothelial Growth FactorVascular Endothelial Growth Factor A

Substanzen

Angiopoietin-1Angiopoietin-2Vascular Endothelial Growth Factor AReceptors, Vascular Endothelial Growth Factor

Autor:innen und Institutionen

  • Department of Respiratory Medicine, Graduate School of Medicine, Osaka City University, 1-4-3, Asahi-machi, Abenoku, Osaka, 545-8585, Japan. kanazawa-h@med.osaka-cu.ac.jp

Zitieren

APA

Kanazawa, H. (2007). VEGF, Angiopoietin-1 and -2 in Bronchial Asthma: New Molecular Targets in Airway Angiogenesis and Microvascular Remodeling. Recent Patents on Inflammation & Allergy Drug Discovery. https://doi.org/10.2174/187221307779815066

Vancouver

Kanazawa H. VEGF, Angiopoietin-1 and -2 in Bronchial Asthma: New Molecular Targets in Airway Angiogenesis and Microvascular Remodeling. Recent Patents on Inflammation & Allergy Drug Discovery. 2007. doi:10.2174/187221307779815066

BibTeX
@article{Kanazawa2007,
  author = {Kanazawa, Hiroshi},
  title = {VEGF, Angiopoietin-1 and -2 in Bronchial Asthma: New Molecular Targets in Airway Angiogenesis and Microvascular Remodeling},
  journal = {Recent Patents on Inflammation & Allergy Drug Discovery},
  year = {2007},
  doi = {10.2174/187221307779815066}
}
Kostenlos starten →